Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

New gene therapy for 'bubble boy' disease appears effective and safe

A new form of gene therapy for boys with X-linked severe combined immunodeficiency syndrome (SCID-X1), a life-threatening condition also known as "bubble boy" disease, appears to be both effective and safe, according to a collaborative research team from Dana-Farber/Boston Children's Cancer and Blood Disorders Center and other institutions conducting an international clinical trial.

Early data suggest that the therapy may avoid the late-developing leukaemia seen in a quarter of SCID-X1 patients in pioneering gene therapy trials in Europe more than a decade ago.

Eight of nine boys recruited to date onto the trial are alive between 12 and 38 months after treatment, with no SCID-X1-associated infections, the research team reported in the New England Journal of Medicine.

Gene therapy alone generated functioning immune systems in seven of the eight.

Genetic studies of the boys' new T-cells, which are critical components of the body's immune system, reveal that the viral vector used to deliver the gene therapy did not lead to an expansion of cells with vector insertions near known cancer-causing genes, raising cautious hopes about the vector's long-term safety.

One child died of an overwhelming infection present at the time gene therapy began.

Left untreated, boys with SCID-X1 usually die of infection before their first birthday.

The investigators will continue to monitor the patients for any signs of treatment-related leukaemia for 15 years.

In the prior European trials — which were the first to demonstrate gene therapy's potential to successfully cure a disease — leukaemia appeared two to five years after treatment.

This outcome was one of several events that together slowed clinical progress in gene therapy for many years.

The modified vector created for the current trial is a self-inactivating gammaretrovirus, designed to deliver its payload effectively while minimising the chance of inadvertently turning on genes, called oncogenes, that could lead to leukaemia.

"Our goal was to take the molecular data from the prior trial and use it to produce a vector that would remain effective and at the same time reduce the risk of leukaemia," said David A. Williams, MD, a leader of Dana-Farber/Boston Children's, chief of the Division of Hematology/Oncology and director of clinical and translational research at Boston Children's Hospital, principal investigator for the gene therapy trial's US sites, and corresponding senior author of the NEJM paper.

"The efficacy data from our study is clear: The vector does work to correct the disease. And by a surrogate endpoint, we have improved the treatment's safety, although it's too early to say that we've completely eliminated the long-term risk of leukaemia."

After a single round of treatment, six of the seven boys for whom the gene therapy was successful had achieved the trial's primary efficacy endpoints — a T-cell count greater than 300 cells per microliter of blood and T-cell proliferation in response to stimulation with phytohemagglutinin (a test used to measure T-cells' ability to react to pathogens).

The seventh boy received a second round of gene therapy and remains healthy despite having relatively low T-cell counts.

The eighth surviving patient was successfully treated with a conventional haematopoietic (blood-forming) stem cell transplant after gene therapy failed to stimulate T-cell production.

"Only a minority of babies with SCID-X1 have the optimal donor for standard transplant, a brother or sister who is tissue-type matched," said co-lead author Sung-Yun Pai, MD, a paediatric haematologist/oncologist at Dana-Farber/Boston Children's.

"For the rest, gene therapy is a therapeutic option that avoids the need to find an alternative donor and avoids complications of allogeneic transplant such as graft-versus-host-disease."

The core question of the trial was whether the new self-inactivating viral vector could safely and successfully shuttle a gene called the IL-2 receptor gamma (IL2RG) subunit into the patients' haematopoietic stem cells.

In boys born with SCID-X1, mutations render the IL2RG gene inactive, robbing the children of the ability to produce a functional immune system.

Source: Dana-Farber Cancer Institute



Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation